Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 191

1.

Expression of epithelial cell adhesion molecule in paired tumor samples of patients with primary and recurrent serous ovarian cancer.

Pietzner K, Woopen H, Richter R, Joens T, Braicu EI, Dimitrova D, Mellstedt H, Darb-Esfahani S, Denkert C, Lindhofer H, Fotopoulou C, Sehouli J.

Int J Gynecol Cancer. 2013 Jun;23(5):797-802. doi: 10.1097/IGC.0b013e3182929056.

PMID:
23694980
2.

Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer.

Woopen H, Pietzner K, Richter R, Fotopoulou C, Joens T, Braicu EI, Mellstedt H, Mahner S, Lindhofer H, Darb-Esfahani S, Denkert C, Sehouli J.

J Gynecol Oncol. 2014 Jul;25(3):221-8. doi: 10.3802/jgo.2014.25.3.221.

3.

Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.

Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

Int J Gynecol Cancer. 2009 Jul;19(5):860-6. doi: 10.1111/IGC.0b013e3181a8331f.

PMID:
19574774
4.

Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.

Elzarkaa AA, Sabaa BE, Abdelkhalik D, Mansour H, Melis M, Shaalan W, Farouk M, Malik E, Soliman AA.

J Cancer Res Clin Oncol. 2016 May;142(5):949-58. doi: 10.1007/s00432-016-2116-5.

PMID:
26762850
5.

Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer.

Benko G, Spajić B, Krušlin B, Tomas D.

Urol Oncol. 2013 May;31(4):468-74. doi: 10.1016/j.urolonc.2011.03.007.

PMID:
21514185
6.

Overexpression of epithelial cell adhesion molecule protein is associated with favorable prognosis in an unselected cohort of ovarian cancer patients.

Battista MJ, Cotarelo C, Jakobi S, Steetskamp J, Makris G, Sicking I, Weyer V, Schmidt M.

J Cancer Res Clin Oncol. 2014 Jul;140(7):1097-102. doi: 10.1007/s00432-014-1672-9.

PMID:
24728493
7.

Prognostic significance of paired epithelial cell adhesion molecule and E-cadherin in ovarian serous carcinoma.

Shim HS, Yoon BS, Cho NH.

Hum Pathol. 2009 May;40(5):693-8. doi: 10.1016/j.humpath.2008.10.013.

PMID:
19157508
8.

Microparticles from ovarian carcinomas are shed into ascites and promote cell migration.

Press JZ, Reyes M, Pitteri SJ, Pennil C, Garcia R, Goff BA, Hanash SM, Swisher EM.

Int J Gynecol Cancer. 2012 May;22(4):546-52. doi: 10.1097/IGC.0b013e318241d9b9.

PMID:
22315094
9.

Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma.

Kerr EH, Frederick PJ, Egger ME, Stockard CR, Sellers J, DellaManna D, Oelschlager DK, Amm HM, Eltoum IE, Straughn JM, Buchsbaum DJ, Grizzle WE, McNally LR.

Ann Surg Oncol. 2013 Sep;20(9):3059-65. doi: 10.1245/s10434-013-2878-9.

PMID:
23525731
10.

Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation.

Ricciardelli C, Lokman NA, Cheruvu S, Tan IA, Ween MP, Pyragius CE, Ruszkiewicz A, Hoffmann P, Oehler MK.

Clin Exp Metastasis. 2015 Jun;32(5):441-55. doi: 10.1007/s10585-015-9718-1.

PMID:
25895698
11.

Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma.

Sung PL, Jan YH, Lin SC, Huang CC, Lin H, Wen KC, Chao KC, Lai CR, Wang PH, Chuang CM, Wu HH, Twu NF, Yen MS, Hsiao M, Huang CY.

Oncotarget. 2016 Jan 26;7(4):4036-47. doi: 10.18632/oncotarget.6700.

12.

The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.

Silva EG, Gershenson DM, Malpica A, Deavers M.

Am J Surg Pathol. 2006 Nov;30(11):1367-71.

PMID:
17063075
13.

Elevated growth differentiation factor 15 expression predicts poor prognosis in epithelial ovarian cancer patients.

Zhang Y, Hua W, Niu LC, Li SM, Wang YM, Shang L, Zhang C, Li WN, Wang R, Chen BL, Xin XY, Zhang YQ, Wang J.

Tumour Biol. 2016 Jul;37(7):9423-31. doi: 10.1007/s13277-015-4699-x. Erratum in: Tumour Biol. 2016 Jun;37(6):8465.

PMID:
26781874
14.

Folate receptor alpha as a tumor target in epithelial ovarian cancer.

Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL, Hartmann LC.

Gynecol Oncol. 2008 Mar;108(3):619-26. doi: 10.1016/j.ygyno.2007.11.020.

15.

Expression of EpCAM and prognosis in early-stage glottic cancer treated by radiotherapy.

Murakami N, Mori T, Yoshimoto S, Ito Y, Kobayashi K, Ken H, Kitaguchi M, Sekii S, Takahashi K, Yoshio K, Inaba K, Morota M, Sumi M, Itami J.

Laryngoscope. 2014 Nov;124(11):E431-6. doi: 10.1002/lary.24839.

16.

Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.

Fotopoulou C, Zang R, Gultekin M, Cibula D, Ayhan A, Liu D, Richter R, Braicu I, Mahner S, Harter P, Trillsch F, Kumar S, Peiretti M, Dowdy SC, Maggioni A, Trope C, Sehouli J.

Ann Surg Oncol. 2013 Apr;20(4):1348-54. doi: 10.1245/s10434-012-2673-z.

PMID:
23054114
17.

Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.

Grisham RN, Iyer G, Sala E, Zhou Q, Iasonos A, DeLair D, Hyman DM, Aghajanian C.

Int J Gynecol Cancer. 2014 Jul;24(6):1010-4. doi: 10.1097/IGC.0000000000000190.

18.

HSP60 predicts survival in advanced serous ovarian cancer.

Hjerpe E, Egyhazi S, Carlson J, Stolt MF, Schedvins K, Johansson H, Shoshan M, Avall-Lundqvist E.

Int J Gynecol Cancer. 2013 Mar;23(3):448-55. doi: 10.1097/IGC.0b013e318284308b.

PMID:
23429486
19.

Expression of p16, p53, CD24, EpCAM and calretinin in serous borderline tumors of the ovary.

Aktaş IY, Buğdayci M, Usubütün A.

Turk Patoloji Derg. 2012;28(3):220-30. doi: 10.5146/tjpath.2012.01128.

20.

Pooled analysis of the prognostic relevance of disseminated tumor cells in the bone marrow of patients with ovarian cancer.

Fehm T, Banys M, Rack B, Janni W, Marth C, Blassl C, Hartkopf A, Trope C, Kimmig R, Krawczyk N, Wallwiener D, Wimberger P, Kasimir-Bauer S.

Int J Gynecol Cancer. 2013 Jun;23(5):839-45. doi: 10.1097/IGC.0b013e3182907109.

PMID:
23694981

Supplemental Content

Support Center